Get the Stockscreener App
0.305
7.60%
-0.0251
After Hours:
.32
0.015
+4.92%
Acurx Pharmaceuticals Inc stock is traded at $0.305, with a volume of 375.53K.
It is down -7.60% in the last 24 hours and down -19.72% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$0.3301
Open:
$0.33
24h Volume:
375.53K
Relative Volume:
2.10
Market Cap:
$8.15M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.2652
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-12.10%
1M Performance:
-19.72%
6M Performance:
-64.33%
1Y Performance:
-87.70%
1-Day Range:
$0.304
$0.33
1-Week Range:
$0.304
$0.37
52-Week Range:
$0.30
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.305 | 8.15M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - Akron Beacon Journal
Acurx Pharmaceuticals Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA pol IIIC Inhibitors - marketscreener.com
Acurx (ACXP) Advances Antibiotic Candidate for C. difficile Treatment | ACXP Stock News - GuruFocus
Warner Bros. Discovery to split into two companies, dividing cable and streaming services - WFMZ.com
Breakthrough: New Antibiotic Class Shows Promise Against Drug-Resistant C. DifficilePhase 3 Ready - Stock Titan
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
GameStop adds Bitcoin to its treasury | NYSE:GME - Proactive financial news
Chikungunya wins boost Valneva; overall infectious disease stocks fall - BioWorld MedTech
ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus
ACXP Stock: Selling Stockholder to Offload Shares with No Proceeds to Company | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling StockholderSEC Filing - marketscreener.com
Q2 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment - MSN
Acurx Pharmaceuticals’ Earnings Call: Progress Amidst Funding Challenges - TipRanks
ACXP: Acurx Pharmaceuticals Receives 'Buy' Rating from HC Wainwr - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock - Investing.com Australia
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 T - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock By Investing.com - Investing.com India
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 Target | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports Improved Q1 2025 Results - TipRanks
Earnings call transcript: Acurx Pharmaceuticals beats Q1 2025 EPS forecast By Investing.com - Investing.com India
Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million - marketscreener.com
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Tesla Stock Is Climbing Monday: What's Going On?Tesla (NASDAQ:TSLA) - Benzinga
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement - TipRanks
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y - Yahoo Finance
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week" - Seeking Alpha
Acurx Pharmaceuticals To Discuss First Quarter 2025 Financial Results - TradingView
Acurx Pharmaceuticals to Reveal Q1 2025 Financial Performance and Key Pipeline Updates - Stock Titan
Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan
A tiny internet company's stock spiked 335% on plans to mimic Michael Saylor's crypto playbook - Business Insider
Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada
Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com
Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan
Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - standard-journal.com
Press Release Distribution & PR Platform - ACCESS Newswire
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Acurx Pharmaceuticals announces resale of 8.4M shares - MSN
10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey
Acurx Pharmaceuticals, Inc. (ACXP): Insider Were Buying In Q1 2025 - Insider Monkey
ACXP stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Acurx Pharmaceuticals Inc (ACXP) Q4 2024 Earnings Call Highlights: Advancing Antibiotic Trials ... By GuruFocus - Investing.com Canada
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know - MSN
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):